Neulastim

FN risk assessment mobile application is primarily a risk factor assessment tool for Febrile Neutropenia that is associated with chemotherapy regimen for cancer patients.

This app is intended to help HCPs to identify / prevent potential risks of developing FN before during and after chemotherapy sessions.

1. FN risk factor assessment:
Total risk of FN is based not only on chemotherapy regimen risk but also on individual patient risk profile.

Through series of questions in multiple selection form the app assesses the patient profile, determines the risk and informs the HCP of the recommended treatment option.

2. EORTC Guidelines
2010 EORTC guidelines for the use of primary prophylaxis in adult cancer patients at risk of chemotherapy-induced febrile neutropenia (FN)

3. About Neulastim®
Know more about the medicinal product, qualitative & quantitative composition, pharmaceutical form and clinical particulars,...